Bristol-Myers Squibb Co. inked a collaboration and licensing deal with Jiangsu Hengrui Pharmaceuticals Co. that could be valued at as much as $15.2 billion, as the US drugmaker seeks to leverage China’s efficiency in early development.
The agreement includes a portfolio of 13 early-stage programs in oncology, hematology and immunology, the companies said in a statement Tuesday. Bristol-Myers will pay Hengrui as much as $950 million by 2028, including $600 million up front.
Hengrui’s shares surged as much as 16% in Hong Kong on Tuesday and by the 10% daily limit in Shanghai before paring some of the gains. The ...
